切换至 "中华医学电子期刊资源库"
高级检索
中华诊断学电子杂志

中华诊断学电子杂志 ›› 2024, Vol. 12 ›› Issue (01) : 69 -72. doi: 10.3877/cma.j.issn.2095-655X.2024.01.012

综述

免疫检查点抑制剂在治疗转移性去势抵抗性前列腺癌中的研究进展
吕泉龙1, 史文杰2, 孙文国1,†()   
  1. 1. 541001　桂林医学院附属医院泌尿外科
    2. 541001　桂林医学院附属医院乳腺科
  • 收稿日期:2023-11-30 出版日期:2024-02-26
  • 通信作者: 孙文国
  • 基金资助:
    国家自然科学基金(82160463); 桂林市科学研究与技术开发项目(20210227-7-4); 广西状族自治区卫生健康委员会自筹经费科研项目(Z20200131)

Research advances of immune checkpoint inhibitors in the treatment of metastatic castration-resistant prostate cancer

Quanlong Lyu1, Wenjie Shi2, Wenguo Sun1,†()   

  1. 1. Department of Urology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
    2. Department of Breast, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
  • Received:2023-11-30 Published:2024-02-26
  • Corresponding author: Wenguo Sun
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

吕泉龙, 史文杰, 孙文国. 免疫检查点抑制剂在治疗转移性去势抵抗性前列腺癌中的研究进展[J]. 中华诊断学电子杂志, 2024, 12(01): 69-72.

Quanlong Lyu, Wenjie Shi, Wenguo Sun. Research advances of immune checkpoint inhibitors in the treatment of metastatic castration-resistant prostate cancer[J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(01): 69-72.

随着免疫治疗在其他肿瘤领域取得成功，前列腺癌也进入了免疫治疗时代。目前前列腺癌领域研究比较深入的免疫检查点包括CTLA-4、PD-1/PD-L1通路。笔者回顾了近年来免疫检查点抑制剂单药或联合治疗在晚期前列腺癌患者的研究进展，探讨其发展方向及应用前景。

关键词: 前列腺癌, 免疫检查点抑制剂, 免疫治疗, 细胞毒性T淋巴细胞抗原4, 程序性死亡受体1

With the success of immunotherapy in other oncology areas, prostate cancer has also entered the era of immunotherapy. At present, the immune checkpoints (ICs) in the prostate cancer field have been studied deeply, including CTLA-4 and PD-1/PD-L1 pathways. This article reviews the recent progress of immune checkpoint inhibitors (ICIs) monotherapy or combination therapy in patients with advanced prostate cancer, and discusses its development direction and application prospect.

Key words: Prostate cancer, Immune checkpoint inhibitors, Immunotherapy, Cytotoxic T lymphocyte antigen, Programmed death-1
[1]
Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2021，71(3)：209-249.DOI：10.3322/caac.21660.
[2]
Parker C, Castro E, Fizazi K, et al.Prostate cancer：ESMO clinical practice guidelines for diagnosis，treatment and follow-up[J].Ann Oncol，2020，31(9)：1119-1134.DOI：10.1016/j.annonc.2020.06.011.
[3]
Cornford P, van den Bergh R, Briers E, et al.EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer.Part II-2020 update：treatment of relapsing and metastatic prostate cancer[J].Eur Urol，2021，79(2)：263-282.DOI：10.1016/j.eururo.2020.09.046.
[4]
孔琪，王章桂．晚期前列腺癌治疗进展[J].实用医学杂志，2021，37(3)：410-414.DOI：10.3969/j.issn.1006-5725.2021.01.027.
[5]
Nuhn P, De Bono JS, Fizazi K, et al.Update on systemic prostate cancer therapies：management of metastatic castration-resistant prostate cancer in the era of precision oncology[J].Eur Urol，2019，75(1)：88-99.DOI：10.1016/j.eururo.2018.03.028.
[6]
宋若飘，臧爱民，贾友超．PD-L1在肿瘤细胞中表达调控机制研究进展[J].实用医学杂志，2020，36(10)：1286-1291.DOI：10.3969/j.issn.1006-5725.2020.10.005.
[7]
Farhangnia P, Ghomi SM, Akbarpour M, et al.Bispecific antibodies targeting CTLA-4：game-changer troopers in cancer immunotherapy[J].Front Immunol，2023(14)：1155778.DOI：10.3389/fimmu.2023.1155778.
[8]
Isaacsson Velho P, Antonarakis ES.PD-1/PD-L1 pathway inhibitors in advanced prostate cancer[J].Expert Rev Clin Pharmacol，2018，11(5)：475-486.DOI：10.1080/17512433.2018.1464388.
[9]
Xu Y, Song G, Xie S, et al. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer[J].Mol Ther，2021，29(6)：1958-1969.DOI：10.1016/j.ymthe.2021.04.029.
[10]
Hossen MM, Ma Y, Yin Z, et al.Current understanding of CTLA-4：from mechanism to autoimmune diseases[J].Front Immunol，2023(14)：1198365.DOI：10.3389/fimmu.2023.1198365.
[11]
Wei SC, Duffy CR, Allison JP.Fundamental mechanisms of immune checkpoint blockade therapy[J].Cancer Discov，2018，8(9)：1069-1086.DOI：10.1158/2159-8290.CD-18-0367.
[12]
Kwon J, Bryant RJ, Parkes EE.The tumor microenvironment and immune responses in prostate cancer patients[J].Endocr Relat Cancer，2021，28(8)：T95-T107.DOI：10.1530/ERC-21-0149.
[13]
Subudhi SK, Vence L, Zhao H, et al.Neoantigen responses，immune correlates，and favorable outcomes after ipilimumab treatment of patients with prostate cancer[J].Sci Transl Med，2020，12(537)：eaaz3577 [pii].DOI：10.1126/scitranslmed.aaz3577.
[14]
Kwon ED, Drake CG, Scher HI, et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043)：a multicentre，randomised，double-blind，phase 3 trial[J].Lancet Oncol，2014，15(7)：700-712.DOI：10.1016/S1470-2045(14)70189-5.
[15]
Fizazi K, Drake CG, Beer TM, et al.Final analysis of the ipilimumab versus placebo following radiotherapy phase iii trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors[J].Eur Urol，2020，78(6)：822-830.DOI：10.1016/j.eururo.2020.07.032.
[16]
Beer TM, Logothetis C, Sharma P, et al.CA184-095：a randomized，double-blind，phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)[J].J Clin Oncol，2013，31(1)：15-16.DOI：10.1186/1477-7819-11-101.
[17]
Beer TM, Kwon ED, Drake CG, et al.Randomized，double-blind，phase Ⅲ trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer[J].J Clin Oncol，2017，35(1)：40-47.DOI：10.1200/JCO.2016.69.1584.
[18]
Jafari S, Molavi O, Kahroba H, et al.Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer[J].Cell Mol Life Sci，2020，77(19)：3693-3710.DOI：10.1007/s00018-020-03459-1.
[19]
Antonarakis ES, Piulats JM, Gross-Goupil M, et al.Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer：multicohort，open-label phase Ⅱ KEYNOTE-199 study[J].J Clin Oncol，2020，38(5)：395-405.DOI：10.1200/JCO.19.01638.
[20]
Abida W, Cheng ML, Armenia J, et al.Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade[J].JAMA Oncol，2019，5(4)：471-478.DOI：10.1001/jamaoncol.2018.5801.
[21]
Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA[J].J Immunother Cancer，2020，8(2)：e001065.DOI：10.1136/jitc-2020-001065.
[22]
Graham LS, Montgomery B, Cheng HH, et al. Mismatch repair deficiency in metastatic prostate cancer：response to PD-1 blockade and standard therapies[J].PLoS One，2020，15(5)：e0233260.DOI：10.1371/journal.pone.0233260.
[23]
Hansen AR, Massard C, Ott PA, et al.Pembrolizumab for advanced prostate adenocarcinoma：findings of the KEYNOTE-028 study[J].Ann Oncol，2018，29(8)：1807-1813.DOI：10.1093/annonc/mdy232.
[24]
Petrylak DP, Loriot Y, Shaffer DR, et al.Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer：a phase i study[J].Clin Cancer Res，2021，27(12)：3360-3369.DOI：10.1158/1078-0432.CCR-20-1981.
[25]
Vitkin N, Nersesian S, Siemens DR, et al. The tumor immune contexture of prostate cancer[J].Front Immunol，2019(10)：603.DOI：10.3389/fimmu.2019.00603.
[26]
Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer：preliminary analysis of patients in the checkmate 650 trial[J].Cancer Cell，2020，38(4)：489-499.e3.DOI：10.1016/j.ccell.2020.08.007.
[27]
Long X, Hou H, Wang X, et al.Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration[J].Cell Death Dis，2020，11(9)：779.DOI：10.1038/s41419-020-02973-1.
[28]
Graff JN, Antonarakis ES, Hoimes CJ, et al. Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC)：KEYNOTE-199 cohorts 4-5[J].J Clini Oncol，2020，38(6_suppl)：15.DOI：10.1200/JCO.2020.38.6_suppl.15.
[29]
Graff JN, Beer TM, Alumkal JJ, et al.A phase Ⅱ single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone[J].J Immunother Cancer，2020，8(2)：e000642.DOI：10.1136/jitc-2020-000642.
[30]
Petrylak DP, Ratta R, Gafanov R, et al.KEYNOTE-921：phase Ⅲ study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer[J].Future Oncol，2021，17(25)：3291-3299.DOI：10.2217/fon-2020-1133.
[31]
Petrylak DP, Li B, Schloss C, et al.KEYNOTE-921：Phase Ⅲ study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)[J].Ann Onco，2019，30(Supplement_5)：v351.DOI：10.1093/annonc/mdz248.048.
[32]
Drake CG, Saad F, Clark WR, et al.690TiP a phase Ⅲ，randomized，double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX) - ScienceDirect[J].Ann Oncol，2020，31(4)：S546.DOI：10.1016/j.annonc.2020.08.2084.
[33]
Liu D．CAR-T " the living drugs" ，immune checkpoint inhibitors，and precision medicine：a new era of cancer therapy[J].J Hematol Oncol，2019，12(1)：113.DOI：10.1186/s13045-019-0819-1.
[34]
Sam J, Colombetti S, Fauti T, et al.Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity[J].Front Oncol，2020(10)：575737.DOI：10.3389/fonc.2020.575737.
[35]
Daver N．A bispecific approach to improving CAR T cells in AML[J].Blood，2020，135(10)：703-704.DOI：10.1182/blood.2020004791.
[36]
Agarwal N, McGregor B, Maughan BL, et al.Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer：results from an expansion cohort of a multicentre，open-label，phase 1b trial (COSMIC-021)[J].Lancet Oncol，2022，23(7)：899-909.DOI：10.1016/S1470-2045(22)00278-9.
[37]
Cattrini C, España R, Mennitto A, et al.Optimal sequencing and predictive biomarkers in patients with advanced prostate cancer[J].Cancers (Basel)，2021，13(18)：4522.DOI：10.3390/cancers13184522.
[1] 李辉, 尉维录, 吴茂林. 经直肠剪切波弹性成像对存在下尿路症状的前列腺病变良恶性的鉴别诊断价值及其影响因素分析[J]. 中华医学超声杂志（电子版）, 2023, 20(11): 1193-1198.
[2] 方晔, 谢晓红, 罗辉. 品管圈在提高前列腺癌穿刺检出率中的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(07): 722-727.
[3] 尚峰进, 陈陆尧, 刘亚星, 张浩然, 连长红. 肿瘤相关中性粒细胞在胃癌发生发展和治疗中的研究进展[J]. 中华普通外科学文献(电子版), 2024, 18(01): 58-61.
[4] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[5] 李俊涛, 张天佑, 叶雷, 郭强, 吴坚坚, 尧冰, 王德娟, 邱剑光. 保留"尿道系膜"的腹腔镜下前列腺根治性切除术后尿控情况的研究[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 19-24.
[6] 张琳, 吴波, 王东文. 前列腺癌特异性近红外荧光探针的研究进展与展望[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 6-11.
[7] 邓瑞锋, 程璐, 周宇林, 刘远灵, 江文聪, 江敏耀, 江福能, 习明. TGF-β1诱导骨髓间充质干细胞外泌体分泌miR-424-3p促进前列腺癌细胞增殖及转移[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 82-89.
[8] 邓新军, 李正明, 李文彬. 广东省医学会泌尿外科疑难病例多学科会诊（第14期）——左肾原发恶性肿瘤并发于肺癌并脑转移[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 114-117.
[9] 朱迎, 赵征, 许达, 陆录, 殷保兵. 免疫检查点抑制剂治疗肝细胞癌的进展与展望[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 5-10.
[10] 张占国. 靶向免疫治疗时代的肝癌肝切除术再思考[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 11-15.
[11] 张宇, 余灵祥, 杨永平, 赵德希, 刁广浩, 杨木易, 赵亮, 刘佳, 李鹏, 张宁, 任辉. 原发性肝癌Ⅲa期降期后肝切除临床疗效分析[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 78-82.
[12] 严帅, 岳志强, 赵江华, 陈琳, 吴金柱. 初始不可切除肝癌患者靶向免疫联合治疗后手术切除临床疗效[J]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 83-87.
[13] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[14] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[15] 张可, 闫琳琳, 王鹏飞, 章秀林, 赵帆, 胡守奎. 外泌体环状RNA在肿瘤免疫和癌症免疫治疗中的作用[J]. 中华临床医师杂志(电子版), 2023, 17(10): 1102-1108.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号